适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 159
- 试验地点
- 1
- 主要终点
- Efficacy variables Dose response (change from baseline in HbA1c) at stipulated date in each treatment group
研究概览
简要总结
This study was designed to find dose response and as extension in treatment of GW823093C.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
GW823093C A
Placebo Comparator
A=45 mg
干预措施: GW823093C A (Drug)
GW823093C B
Placebo Comparator
B=30 mg
干预措施: GW823093C B (Drug)
GW823093C C
Placebo Comparator
C=15 mg
干预措施: GW823093C C (Drug)
结局指标
主要结局
Efficacy variables Dose response (change from baseline in HbA1c) at stipulated date in each treatment group
时间窗: 12 weeks
次要结局
- Long term safety variables(64 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study Of GW823093 In Japanese Subjects With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00372957GlaxoSmithKline30
终止
2 期
GW873140 In Combination With Combivir In HIV Infected SubjectsInfection, Human Immunodeficiency Virus IHIV InfectionNCT00104429ViiV Healthcare125
进行中（未招募）
1 期
A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)Lymphoma, Non-HodgkinNCT06660563Janssen Research & Development, LLC19
已完成
2 期
A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia DisorderInsomnia DisordersNCT03375203Janssen Research & Development, LLC365
已完成
2 期
An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain ParticipantsPainLow Back PainBack PainOsteoarthritis, KneeNCT01124604Janssen Pharmaceutical K.K.91